PMID- 28272190
OWN - NLM
STAT- MEDLINE
DCOM- 20190802
LR  - 20190802
IS  - 1538-8662 (Electronic)
IS  - 0361-1817 (Linking)
VI  - 42
IP  - 4
DP  - 2017 Apr 16
TI  - Sodium-glucose cotransporter-2 inhibitors: Expanding oral treatment options for 
      type 2 diabetes mellitus.
PG  - 8-15
LID - 10.1097/01.NPR.0000513336.46697.77 [doi]
AB  - The number of patients with type 2 diabetes mellitus (T2DM) continues to increase 
      in the United States. Glycemic control among patients with diabetes is important 
      to prevent future complications, including microvascular and macrovascular 
      disease. A novel class of medications, sodium-glucose cotransporter-2 inhibitors, 
      presents an additional oral treatment option for patients with T2DM.
FAU - Ashjian, Emily
AU  - Ashjian E
AD  - Emily Ashjian is a clinical pharmacist in ambulatory care at the University of 
      Michigan Health System, Ann Arbor, Mich. Jeffrey Tingen is a clinical pharmacist 
      in ambulatory care at the Department of Pharmacy Services at the University of 
      Virginia Health System, Charlottesville, Va.
FAU - Tingen, Jeffrey
AU  - Tingen J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Nurse Pract
JT  - The Nurse practitioner
JID - 7603663
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
MH  - Administration, Oral
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Approval
MH  - Humans
MH  - Sodium-Glucose Transporter 2 Inhibitors/*administration & dosage
MH  - United States
MH  - United States Food and Drug Administration
EDAT- 2017/03/09 06:00
MHDA- 2019/08/03 06:00
CRDT- 2017/03/09 06:00
PHST- 2017/03/09 06:00 [pubmed]
PHST- 2019/08/03 06:00 [medline]
PHST- 2017/03/09 06:00 [entrez]
AID - 10.1097/01.NPR.0000513336.46697.77 [doi]
PST - ppublish
SO  - Nurse Pract. 2017 Apr 16;42(4):8-15. doi: 10.1097/01.NPR.0000513336.46697.77.